As previously reported, RBC Capital analyst Sean Dodge initiated coverage of Privia Health with an Outperform rating and $36 price target. The company’s "capital-light" physician-enablement model makes it "currently and comfortably" free cash flow positive and works with all types of providers and patient-types, which differs from others in the space, the firm noted. The firm is seeing "encouraging evidence" that the broader shift to value is accelerating, which it sees supporting management’s long-term guidance for 20% topline and 30% EBITDA growth, RBC added.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRVA:
- Privia Health management to meet with BTIG
- Privia Health, OhioHealth enter partnership agreement
- Privia Health and OhioHealth Health System Sign Definitive Partnership
- Privia Health sees FY23 GAAP revenue $1.55B-$1.65B, consensus $2.74B
- Privia Health Reports Fourth Quarter 2022 Financial Results
Questions or Comments about the article? Write to editor@tipranks.com